If you've ever dealt with chronic migraines, you know the drill. A GP referral that takes weeks. A neurologist who has fifteen minutes. A prescription scribbled on a pad. Then silence until the next episode sends you back to square one. The care pathway for migraine and related neurological conditions is, to put it plainly, a mess.

Copenhagen-based Hemi Health has raised EUR 4 million in seed funding to do something about it. The round was led by EIFO and Swiss Health Ventures, with continued backing from Sondo Capital, Alliance Venture Capital, and Crowberry Capital. The new capital will fund expansion into the Netherlands as the company's first international market and accelerate development of its AI-powered platform.

Hemi Health blends something you don't see often in digital health: actual physical clinics paired with a proprietary digital platform. It's not an app pretending to replace a doctor. It's a coordinated system that uses both.

Founded in 2023 by Anna Lofqvist, Benedicte Grytte Dahl, Sune K-Holm Nielsen, and Mathias Iversen, Hemi Health is a female-led specialty care provider focused on migraine, headache disorders, and long-term symptoms from concussions and whiplash. The founding team brings a mix of clinical experience and personal motivation.

"Living with migraine myself, I know how exhausting complex care pathways can be," Lofqvist said in the company's announcement. "Across neurological conditions, people often face the same challenge. Navigating care without clarity or continuity. We built Hemi to meet people where they are and provide the structure, coordination, and measurable progress that allows them to move forward and return to everyday life."

There's something about healthtech companies where the founder has lived the problem. It shows up in the product decisions, in the refusal to accept the status quo as tolerable. Hemi's model centers on structured diagnostics, individualized care plans, and continuous monitoring through its app. Patients get video consultations, ongoing communication with their care team, and coordinated multidisciplinary treatment. The emphasis throughout is on measurable outcomes and functional improvement.

The founding team's clinical approach sets Hemi apart from the wave of consumer health apps that have flooded the market in recent years. Most migraine apps offer symptom tracking and trigger logging, which is useful but limited. Tracking when your migraines happen doesn't fix the underlying problem. Hemi's model involves actual clinicians delivering actual treatment through a coordinated pathway. The digital platform supports that clinical work, it doesn't replace it. That distinction matters because regulators, insurers, and patients all respond differently to a company that provides care versus one that provides tracking.

The numbers behind migraine rarely get the attention they deserve. Over one billion people globally live with migraine, making it the third most prevalent illness worldwide. It's the leading cause of disability among people under 50. In Europe alone, the estimated annual cost of migraine exceeds EUR 100 billion when you factor in lost productivity, healthcare utilization, and reduced quality of life.

Yet treatment pathways remain fragmented almost everywhere. Patients bounce between GPs, neurologists, physiotherapists, and psychologists with little coordination between providers. Records don't follow the patient. Treatment plans get lost in handoffs. Progress isn't tracked systematically. For a condition that responds well to structured, consistent management, the current standard of care is remarkably inconsistent.

Concussion and whiplash care face similar challenges. Post-concussion syndrome can persist for months or years, with symptoms including persistent headaches, cognitive difficulties, and emotional changes. Treatment typically involves multiple specialists, physiotherapy, cognitive rehabilitation, and sometimes psychological support, all of which need to be coordinated to be effective. The standard experience for a concussion patient involves being told to rest, coming back in two weeks, and hoping things improve. Hemi's structured approach replaces that wait-and-hope model with active, tracked management.

Hemi is trying to collapse that fragmented journey into a single, coordinated experience. The hybrid model matters because some aspects of neurological care genuinely require in-person assessment. You can't fully evaluate a concussion patient through a screen. But much of the ongoing management, the check-ins, the treatment adjustments, the progress tracking, can happen digitally, and often should.

The investor mix behind this round tells its own story. EIFO, Denmark's export and investment fund, brings government-backed credibility and connections within the Danish healthcare system. Swiss Health Ventures provides expertise in insurance-driven healthcare markets, precisely the kind of knowledge Hemi needs as it expands into the Netherlands and beyond. The returning backers, Sondo Capital from Denmark, Alliance Venture from Norway, and Crowberry Capital from Iceland, represent a pan-Nordic investor coalition that reflects the company's ambition to build across the region.

The choice of the Netherlands as Hemi's first international market isn't random. The Dutch healthcare system is insurance-based, with a strong emphasis on structured care pathways and evidence-based outcomes. Insurers there are increasingly open to digital health solutions that can demonstrate measurable improvements in patient outcomes and cost efficiency. For a company whose entire model is built around structured, data-driven care, it's a natural fit.

The Netherlands also serves as a useful beachhead for broader European expansion. If Hemi can prove its model works within the Dutch insurance framework, the playbook becomes replicable across other insurance-driven markets in Europe. Germany, with its massive healthcare market and growing appetite for digital health applications, would be the obvious next step.

Hemi Health sits at the intersection of several trends that are reshaping healthcare delivery. The shift toward value-based care, which rewards outcomes rather than volume of procedures. The maturation of digital health tools that can actually support clinical decision-making rather than just scheduling appointments. And the growing recognition that chronic conditions like migraine need structured, longitudinal management rather than episodic treatment. The company reported its findings to ArcticStartup on its vision for scalable specialty care.

The company's decision to build physical clinics alongside its digital platform also positions it differently for partnerships with established healthcare systems. Hospitals and insurance companies are increasingly wary of pure-play digital health solutions that promise clinical outcomes without clinical infrastructure. Hemi's hybrid model provides the physical touchpoints that healthcare buyers want while using technology to make those touchpoints more efficient and their outcomes more measurable. It's a harder model to scale than a pure software play, but it may prove more durable.

The female-led founding team also reflects a broader and welcome shift in Nordic healthtech. Women remain underrepresented as startup founders across the region, but the pipeline is changing. Hemi joins a growing cohort of women-founded health companies in the Nordics that are building real businesses around problems they understand firsthand.

The most interesting aspect of Hemi's business model isn't the technology or even the clinical approach. It's the insurance alignment. By building structured care pathways with measurable outcomes, the company is creating the kind of evidence base that health insurers desperately want. Insurers are tired of paying for treatments without knowing whether they work. Hemi's platform tracks patient outcomes systematically, generating data that can demonstrate clinical effectiveness and, crucially, cost effectiveness over time.

This positions the company for reimbursement relationships that are fundamentally different from the fee-for-service model that dominates most healthcare. If Hemi can show insurers that its coordinated care model reduces emergency department visits, decreases medication costs, and improves return-to-work rates for migraine patients, the economic argument for coverage becomes compelling. That kind of evidence takes time to build, which is why the seed stage investment in infrastructure and data collection matters so much. The companies that win in digital health are increasingly the ones that can speak the language of health economics, not just clinical outcomes.

Copenhagen's healthcare innovation scene has been building quietly but steadily. Companies like Corti in clinical AI, Hedia in diabetes management, and now Hemi Health in neurology are creating a cluster of health companies that leverage Denmark's strong clinical research infrastructure and its universal healthcare system as both a testing ground and an initial market. The country's small size, which limits domestic growth potential, also makes it an ideal controlled environment for proving out clinical models before scaling internationally.

The global digital health market is expected to exceed $500 billion by 2028, and specialty care platforms represent one of the fastest-growing segments within it. But the companies that scale successfully in this space share a common trait: they build clinical credibility first and growth second. Hemi's choice to start with physical clinics, to hire actual neurologists and physiotherapists before scaling its app, reflects this understanding. You can always add digital features to a clinic. It's much harder to add clinical credibility to an app.

EUR 4 million is a modest seed round by the standards of Nordic tech fundraising in 2026. But the size of the round matters less than what the company does with it. If Hemi can prove that structured, hybrid care for neurological conditions produces better outcomes at manageable cost, the market opportunity is enormous. One billion potential patients tend to get investors' attention, eventually.